These findings reveal the important role of METTL3-IGF2BP3 axis in the invasive and metastatic ability of tumor cells in pancreatic cancer and provide a basis for the clinical targeting of IGF2BP3 to inhibit the invasive and metastatic ability of pancreatic cancer. This evidence concerns the gene IGF2BP3 and pancreatic neoplasm.